UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

Cancer letters, 2007-05, Vol.249 (2), p.271-282

2007

Volltextzugriff (PDF)

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

Annals of oncology, 2009-04, Vol.20 (4), p.674-680

2009

Volltextzugriff (PDF)

Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

Journal of clinical oncology, 2002-12, Vol.20 (23), p.4543-4548

2002

Volltextzugriff (PDF)

Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1512-1518

Louvet, C.

2002

Volltextzugriff (PDF)

Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

Annals of oncology, 2018-10, Vol.29, p.viii375-viii375

2018

Volltextzugriff (PDF)

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method

Annals of oncology, 2018-06, Vol.29, p.v60-v61

2018

Volltextzugriff (PDF)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

British journal of cancer, 2008-10, Vol.99 (8), p.1239-1245

2008

Volltextzugriff (PDF)

A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction

Clinical pharmacology and therapeutics, 2017-08, Vol.102 (2), p.313-320

2017

Volltextzugriff (PDF)

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii736-viii736

2018

Volltextzugriff (PDF)

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer

The pharmacogenomics journal, 2008-08, Vol.8 (4), p.256-267

2008

Volltextzugriff (PDF)

Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1105-1110

1999

Volltextzugriff (PDF)

7LBA Phase 1 dose-expansion study of AMG 900, a pan-Aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors

European journal of cancer (1990), 2014-11, Vol.50, p.197-198

2014

Volltextzugriff (PDF)

Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients

Clinical pharmacology and therapeutics, 2008-03, Vol.83 (3), p.413-415

2008

Volltextzugriff (PDF)

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures

Seminars in oncology, 2002-10, Vol.29 (5), p.21-33, Article asonc02905p0021

2002

Volltextzugriff (PDF)

Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma

Clinical biochemistry, 2007, Vol.40 (1), p.11-17

2007

Volltextzugriff (PDF)

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving Oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer

Clinical cancer research, 2004-06, Vol.10 (12), p.4055-4061

2004

Volltextzugriff (PDF)

Characterization of a new generation of silicon detector: The SIRIUS side “Strippy-Pad” detector

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment, 2021-11, Vol.1015, p.165770, Article 165770

2021

Volltextzugriff (PDF)

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

Cancer, 1996-02, Vol.77 (3), p.441-451

1996

Volltextzugriff (PDF)

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1470-1478

1998

Volltextzugriff (PDF)

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

Annals of oncology, 1996-01, Vol.7 (1), p.95-98

1996

Volltextzugriff (PDF)

Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice: For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003-08, Vol.793 (2), p.357-366

2003

Volltextzugriff (PDF)

Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients

Journal of clinical oncology, 2002-05, Vol.20 (10), p.2551-2558

2002

Volltextzugriff (PDF)

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach

Seminars in oncology, 2017-02, Vol.44 (1), p.13-23

2017

Volltextzugriff (PDF)

Male breast cancer: Results of the treatments and prognostic factors in 397 cases

European journal of cancer (1990), 1995-11, Vol.31 (12), p.1960-1964

1995

Volltextzugriff (PDF)

A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels

Journal of neurophysiology, 2001-05, Vol.85 (5), p.2293-2297

2001

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(281)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(140)
Humans
(97)
Life Sciences & Biomedicine
(89)
Oncology
(62)
Female
(61)
Middle Aged
(59)
Aged
(58)
Biological And Medical Sciences
(56)
Physical Sciences
(56)
Male
(55)
Adult
(53)
Medical Sciences
(53)
Chemistry
(44)
Pharmacology. Drug Treatments
(35)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Materials Science
(32)
Technology
(32)
Antineoplastic Agents
(31)
Chemotherapy
(30)
Fluorouracil - Administration & Dosage
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(27)
European Journal Of Cancer
(25)
Journal Of The American Chemical Society
(16)
Annals Of Oncology
(15)
Oncologie
(13)
Bulletin Du Cancer
(11)
La Revue De Medecine Interne
(11)
Chemistry Of Materials
(9)
Nano Letters
(8)
Acs Nano
(7)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study

Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer

Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage

7LBA Phase 1 dose-expansion study of AMG 900, a pan-Aurora kinase inhibitor, in adult patients with advanced taxane-resistant solid tumors

Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures

Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving Oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer

Characterization of a new generation of silicon detector: The SIRIUS side “Strippy-Pad” detector

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice: For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake

Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach

Male breast cancer: Results of the treatments and prognostic factors in 397 cases

A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels

Suchergebnisse filtern